Prurigo nodularis
☆ AI Dermatology — Free Service
Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
relevance score : -100.0%
ReferencesPrurigo nodularis iganda rinogara kwenguva refu rinoratidzwa nemapundu akawanda akasimba uye ma‑nodules, anowanzo kuwanikwa pamativi ekunze emaoko nemakumbo. Mapundu aya anogona kusiyana mumavara kubva kune ruvara rweganda (skin‑toned) kusvika kupingi, uye anokwenya zvikuru. Zvinogona kukanganisa vanhu vemazera ese uye zvinowanzobatana nemamwe mamiriro eganda anokonzera kuputika kusingaperi, sekunge atopic dermatitis. Mishonga yekurapa inosanganisira anti‑itch mishonga yakasimba, zvinodhaka zvinokanganisa immune system, uye mishonga inobata ne‑nervous system. Kutarisira Prurigo nodularis kunowanzoda kurapwa kwenguva refu.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Kurapa kunowanzosanganisira kushandisa makirimu kana majekiseni e‑steroid panzvimbo yakakuvadzwa. Muzviitiko zvakanyanya kuoma kana kusindimara, marapirwo akadai serenje rekurapa kana mishonga inodzvanyirira immune system inogona kudikanwa. Thalidomide ne‑lenalidomide ndizvo sarudzo dzezviitiko zvakakomba, asi dzinogona kuva nemigumisiro yakaipa. Mishonga mitsva (opioid receptor antagonists, neurokinin‑1 receptor antagonists) inoratidza chivimbiso mukurapa prurigo nodularis iine migumisiro shoma kana ichienzaniswa ne‑thalidomide kana lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo ichimiro cheganda chinoratidzwa nekukwenya kwenguva refu (kunogara kwemavhiki matanhatu), maronda ane chekuita neganda, uye nhoroondo yekukwenya kazhinji. Inosanganisira neuroinflammation uye fibrosis muganda.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis idambudziko reganda rinogara kwenguva refu, rinoratidzwa nemapundu anovava. Hatinyatsoziva chii chinokonzera chirwere ichi, asi zvinoita sekunge nyaya dzedziviriro nedzetsinga dzinobatsira mukukwenya‑kukwenya kutenderera. Parizvino, hapana marapirwo akatenderwa neUS FDA akananga Prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Kurapa ― OTC Zvinodhaka
Kugeza nzvimbo yakakuvara nesipo haibatsiri zvachose uye inogona kuipa. Mafuta eOTC steroid anogona kubatsira kubvisa zviratidzo, asi anowanzoda kushandiswa kwemavhiki akawanda kuti avandudze. Kuramba uchitora antihistamines kunobatsirawo kudzikisa kukoira.
#OTC steroid ointment
#OTC antihistamine
○ Kurapwa
#Intralesional triamcinolone injection